Among them, Cdk4/6, an important target for tumor therapy, has shown significant efficacy in late-stage metastatic breast cancer, particularly for HR + and Her2-subtypes, with the clinical application of inhibitors such as palbociclib, ribociclib, and abemaciclib. This evidence concerns the gene ERBB2 and neoplasm.